Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.62 |
| ▸ | GALR3 | O60755 | 1/20 | 0.55 |
| ▸ | NR2F2 | P24468 | 1/20 | 0.55 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | P2RX7 | Q99572 | 3/20 | 0.49 |
| ▸ | CASP1 | P29466 | 1/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.45 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | JAK2 | O60674 | 1/20 | 0.44 |
| ▸ | JAK1 | P23458 | 1/20 | 0.44 |
| ▸ | TYK2 | P29597 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2847244 | 0.86 | MAPT (0.55) | L3MBTL1CYP3A4CYP2C9NPC1RAB9A | |
| SCHEMBL5318479 | 0.83 | MAPT (0.57) | L3MBTL1SMN1; SMN2MEN1KMT2ATSHR | |
| SCHEMBL11099262 | 0.83 | P2RX7 (0.51) | L3MBTL1GALR3NR2F2TAAR1P2RX7 | |
| SCHEMBL838069 | 0.82 | ALDH1A1 (0.53) | L3MBTL1GALR3NR2F2SMN1; SMN2P2RX7 | |
| SCHEMBL11000136 | 0.81 | ERCC1 (0.48) | L3MBTL1SMN1; SMN2CYP3A4CYP2C9MEN1 | |
| SCHEMBL2119177 | 0.81 | MGAM (0.47) | GALR3NR2F2P2RX7CYP3A4CYP2C9 | |
| SCHEMBL15391205 | 0.80 | LMNA (0.52) | CYP3A4CYP2C9MAPT | |
| SCHEMBL31201903 | 0.80 | CYP3A4 (0.53) | L3MBTL1SMN1; SMN2P2RX7CYP3A4CYP2C9 | |
| SCHEMBL5639026 | 0.77 | GALR3 (0.69) | GALR3NR2F2TAAR1SMN1; SMN2P2RX7 | |
| SCHEMBL4914396 | 0.77 | RAB9A (0.58) | L3MBTL1SMN1; SMN2CYP3A4CYP2C9MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8883786-B2 | Glucocorticoid receptor antagonists | HOFFMANN-LA ROCHE INC. (US) | 2014-11-11 | — | — | US | disclosed |
| US-20130045972-A1 | GLUCOCORTICOID RECEPTOR ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2013-02-21 | — | — | US | disclosed |
| US-8143280-B2 | Glucocorticoid receptor antagonists | HOFFMANN-LA ROCHE INC. (US) | 2012-03-27 | — | — | US | disclosed |
| EP-2205562-B1 | 1,1,1-TRIFLUORO-2-HYDROXY-3-PHENYLPROPANE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2011-03-16 | — | — | EP | disclosed |
| EP-2205562-A1 | 1,1,1-TRIFLUORO-2-HYDROXY-3-PHENYLPROPANE DERIVATIVES | F. Hoffmann-Roche AG (CH) | 2010-07-14 | — | — | EP | disclosed |
| US-20090088425-A1 | GLUCOCORTICOID RECEPTOR ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2009-04-02 | — | — | US | disclosed |
| WO-2009040288-A1 | 1,1,1-TRIFLUORO-2-HYDROXY-3-PHENYLPROPANE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2009-04-02 | — | — | WO | disclosed |
| EP-1846389-A1 | IMIDAZOLE DERIVATIVES | F. Hoffmann-Roche AG (CH) | 2007-10-24 | — | — | EP | disclosed |
| WO-2006082002-A1 | IMIDAZOLE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2006-08-10 | — | — | WO | disclosed |
| US-20060173048-A1 | Imidazole derivatives | F. HOFFMAN-LA ROCHE AG (CH) | 2006-08-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090088425-A1 | GLUCOCORTICOID RECEPTOR ANTAGONISTS | NR3C1, NR3C2, MC2R | L3MBTL1 2134/4885GALR3 193/4885NR2F2 397/4885 |
| US-20060173048-A1 | Imidazole derivatives | GRM2, GRM1, GRIN2C | L3MBTL1 3022/4885GALR3 284/4885NR2F2 464/4885 |
| US-20130045972-A1 | GLUCOCORTICOID RECEPTOR ANTAGONISTS | NR3C1, NR3C2, MC2R | L3MBTL1 2134/4885GALR3 193/4885NR2F2 397/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.